UK markets closed
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • FTSE 250

    22,883.39
    +206.11 (+0.91%)
     
  • AIM

    1,232.54
    +4.45 (+0.36%)
     
  • GBP/EUR

    1.1675
    -0.0013 (-0.11%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.10%)
     
  • BTC-GBP

    24,683.20
    +939.43 (+3.96%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • DOW

    35,061.55
    +238.20 (+0.68%)
     
  • CRUDE OIL

    72.17
    +0.26 (+0.36%)
     
  • GOLD FUTURES

    1,802.10
    -3.30 (-0.18%)
     
  • NIKKEI 225

    27,548.00
    +159.80 (+0.58%)
     
  • HANG SENG

    27,321.98
    -401.86 (-1.45%)
     
  • DAX

    15,669.29
    +154.75 (+1.00%)
     
  • CAC 40

    6,568.82
    +87.23 (+1.35%)
     

Global Antiglaucoma Drugs Market Research Report 2021

·4-min read

Dublin, July 15, 2021 (GLOBE NEWSWIRE) -- The "Antiglaucoma Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

The global antiglaucoma drugs market is expected to grow from $5.76 billion in 2020 to $6.47 billion in 2021 at a compound annual growth rate (CAGR) of 12.3%.

Major players in the antiglaucoma drug market are Aerie Pharmaceuticals, Inc., Allergan, Novartis AG, Abbott Healthcare and Johnson & Johnson.

The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $8.17 billion in 2025 at a CAGR of 6%.

The antiglaucoma drug market consists of sales of antiglaucoma drugs which are used in the treatment of glaucoma. Glaucoma is a disease in which the optic nerve is damaged resulting into irreversible loss of vision and it is often associated with increased pressure of the fluid in eye. The market comprises of segments such as alpha agonists, beta blockers, prostaglandins, combined medication and other. The market does not include the sale of biologics used for the treatment of glaucoma.

To get an antiglaucoma drug approved by the United States Food and Drug Administration (USFDA), drug should have comparable intraocular pressure (IOP) lowering efficacy and benefit-to-hazard ration with respect to the benchmark drug. In 2018, Rhopressa (netarsudil) Ophthalmic Solution by Aerie Pharmaceuticals Inc., was approved by the US FDA considering its ability to lower IOP when compared to benchmarked drugs for glaucoma in the market.

Incidence of glaucoma increases with age and due to increase in the geriatric population worldwide, governments are launching initiatives to promote awareness on glaucoma and other eye disorders. For instance, the Vision Health initiative by Centers for Disease Control and Prevention (CDC) in the USA aimed to prevent eye disorders including glaucoma and improve the overall eye health. In Australia, the government funded an eye screening program as part of its Vision 2020 initiative to promote awareness and prevent vision loss among the population suffering from glaucoma and other eye disorders. These government initiatives will stimulate the awareness among the people on glaucoma driving the market for anti-glaucoma drugs.

Anti-glaucoma drugs are facing the risk of patent expiration in the USA and Europe. For instance, travaprost and bimatoprost, which are used in the treatment of glaucoma, will lose its patent in 2021. This will result in the launch of generic form of the drugs that are priced lower than branded drugs thereby reducing the overall market growth.

Companies in the antiglaucoma drugs market are developing combination therapies in the treatment of glaucoma disease due to their ability to lower intraocular pressure in glaucoma patients. Most of the combinations therapies are fixed dose drugs as it offers patient the ease of consumption when compared to non-fixed combinations.

Alcon launched a combination drug, Simbrinza which is fixed combination of Brinzolamide and Brimonidine, to help patients in reducing the intake of multiple drugs for glaucoma. Rocklatan is a combination of a rho kinase inhibitor and a prostaglandin analog. Combigan is a combination of beta blocker and alpha agonist. Cosopt is a combination of beta blocker and carbonic anhydrase inhibitor.

Key Topics Covered:

1. Executive Summary

2. Antiglaucoma Drugs Market Characteristics

3. Antiglaucoma Drugs Market Trends And Strategies

4. Impact Of COVID-19 on Antiglaucoma Drugs

5. Antiglaucoma Drugs Market Size And Growth
5.1. Global Antiglaucoma Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers of the Market
5.1.2. Restraints on The Market
5.2. Global Antiglaucoma Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers of the Market
5.2.2. Restraints on the Market

6. Antiglaucoma Drugs Market Segmentation
6.1. Global Antiglaucoma Drugs Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Alpha Agonist

  • Beta Blockers

  • Prostaglandin Analogs

  • Combined Medication

  • Others

6.2. Global Antiglaucoma Drugs Market, Segmentation By Disease Condition Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Open-Angle Glaucoma

  • Angle-Closure Glaucoma

  • Normal-Tension Glaucoma

  • Congenital Glaucoma

  • Other Types Of Glaucoma

6.3. Global Antiglaucoma Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Hospital Prescription drugs

  • Over-the counter drugs

7. Antiglaucoma Drugs Market Regional And Country Analysis
7.1. Global Antiglaucoma Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Antiglaucoma Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

  • Aerie Pharmaceuticals Inc

  • ALLERGAN

  • Novartis AG

  • Abbott Healthcare

  • Johnson & Johnson

  • Merck & Co

  • Genentech Inc.

  • Pfizer Inc.

  • Bayer AG

  • Santen Pharmaceuticals Company Ltd.

  • Regeneron Pharmaceuticals Inc.

  • Valeant Pharmaceuticals International Inc.

  • F. Hoffmann-La Roche Ltd

  • Hoya Corporation

  • Valeant Pharmaceuticals International Inc.

For more information about this report visit https://www.researchandmarkets.com/r/gnox7s


CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting